The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

Last updated: March 27, 2026
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

4

Condition

Allergy

Allergies & Asthma

Treatment

Skin Testing

Clinical Study ID

NCT07103720
25-001858
RFGA2023-008-27
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and commonly used before, during and after surgical procedures.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Not have a history of an adverse reactions to midazolam, ketamine or ondansetron

  • Ability to understand study procedures and to comply with them for the entire lengthof the study.

  • Contraception is not necessary, and we will include women of reproductivecapability.

Exclusion

Exclusion Criteria:

  • Unstable patients.

  • History of any adverse reaction (allergy or sensitivity) to midazolam, ketamine orondansetron.

  • Pregnant and Pediatric patients

  • Inability or unwillingness of individual or legal guardian/representative to givewritten informed consent.

Study Design

Total Participants: 21
Treatment Group(s): 1
Primary Treatment: Skin Testing
Phase: 4
Study Start date:
November 05, 2025
Estimated Completion Date:
March 10, 2026

Connect with a study center

  • Mayo Clinic Arizona

    Scottsdale, Arizona 85268
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.